Stynus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -44.28%
- Profit Growth -1007.41%
- Ebitda -797.99%
- Net Worth -82.39%
- Total Assets 3.14%
About Stynus Pharmaceuticals
Stynus Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 June 2018 (Six years and seven months 29 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Penchala Maddisetty and Sunitha Thomdam serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24299KA2018PTC114268
- Company No.
114268
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
What products or services does Stynus Pharmaceuticals Private Limited offer?
Stynus Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Process Control Systems & Equipments, Level Controllers, Bird Food, Poultry & Animal Food, Fish Foods.
Who are the key members and board of directors at Stynus Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Penchala Maddisetty  | Director | 26-Jun-2018 | Current |
| Sunitha Thomdam | Director | 26-Jun-2018 | Current |
Financial Performance of Stynus Pharmaceuticals.
Stynus Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 44.28% decrease. The company also saw a substantial fall in profitability, with a 1007.41% decrease in profit. The company's net worth observed a substantial decline by a decrease of 82.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stynus Pharmaceuticals?
In 2022, Stynus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bionus Private LimitedPenchala Maddisetty and Sunitha Thomdam are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stynus Pharmaceuticals?
Unlock and access historical data on people associated with Stynus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stynus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stynus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.